Developing technologies in biodefense research: Computational drug design

Drug Development Research

Volumn 70, Issue 4, 2009, Pages 279-287

  Clark, Matthew ^a   Meshkat, Sia ^a   Talbot, George ^a   Konteatis, Zenon ^a   Ludington, Jennifer ^a   Zou, Jinming ^a   Freedman, Steven J ^a   Wiseman, Jeffrey S ^a  

^a Locus Pharmaceuticals   (United States)

Author keywords

Computation; Drug design; Free energy

Indexed keywords

BIOLOGICAL WARFARE; BIOLOGY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG EFFICACY; ENTROPY; PROTEIN STRUCTURE; REVIEW; SOLVATION; THERMODYNAMICS;

EID: 67649351899     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20305     Document Type: Review

References (43)

1. Bleicher KH, Böhm HJ, Müller K, Alanine AI. 2003. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2:369-378. (Pubitemid 37361707)
2. Bukhtiyarova M, Karpusas M, Northrop K, Namboodiri HVM, Springman EB. 2007. Mutagenesis of p38MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state. Biochemistry 46:5687-5696. (Pubitemid 46764118)
3. Chang CE, Gilson MK. 2004. Free energy, entropy, and induced fit in host-guest recognition: calculations with the second-generation mining minima algorithm. J Am Chem Soc 126:13156-13164. (Pubitemid 39372346)
4. Chen W, Chang CE, Gilson MK. 2004. Calculation of cyclodextrin binding affinities: energy, entropy, and implications for drug design. Biophys J 87:3035-3049. (Pubitemid 40468563)
5. Clark M, Wiseman JS. 2008. Grand canonical competitive simulation of ligands and water. 236th ACS National Meeting, Philadelphia PA. August 17-21. Washington, DC: American Chemical Society. COMP77.
6. Clark M, Guarnieri F, Shkurko I, Wiseman J. 2006. Grand canonical Monte Carlo simulation of ligand-protein binding. J Chem Inf Model 46:231-242. (Pubitemid 43282118)
7. Congreve MS, Davis DJ, Devine L, Granata C, O'Reilly M, Wyatt PG, Jhoti H. 2003. Detection of ligands from a dynamic combinatorial library by X-ray crystallography. Angew Chem Int Ed Engl 42:4479-4482. (Pubitemid 37214518)
8. Deanda F, Smith KM, Liu J, Pearlman RS. 2004. GSSI, a general model for solute-solvent interactions. 1. Description of the model. Mol Pharm 1:23-39.
9. Deng Y, Roux B. 2006. Calculation of standard binding free energies: aromatic molecules in the T4 lysozyme L99A mutant. J Chem Theory Comput 2:1255-1273.
10. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: new estimates of drug development costs. J Health Econ 22:151-185. (Pubitemid 36279392)
11. Eftink MR, Anusiem AC, Bilotonen RL. 1983. Enthalpy-entropy compensation and heat capacity changes for protein-ligand interactions: general thermodynamic models and data for the binding of nucleotides to ribonuclease A. Biochemistry 22:3884-3896.
12. Erickson JA, Jalaie M, Robertson DH, Lewis RA, Vieth M. 2004. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. J Med Chem 47:45-55. (Pubitemid 38040489)
13. Eriksson MA, Pitera J, Kollman PA. 1999. Prediction of the binding free energies of new TIBO-like HIV-1 reverse transcriptase inhibitors using a combination of PROFEC, PB/SA, CMC/MD, and free energy calculations. J Med Chem 42:868-881. (Pubitemid 29136176)
14. Erlanson DA, McDowell RS, O'Brien T. 2004. Fragment-based drug discovery. J Med Chem 47:3463-3482. (Pubitemid 38822007)
15. Food and Drug Administration. 2007. Smallpox (variola) infection: developing drugs for treatment or prevention. Washington DC: FDA.
16. Gilbert J, Henshe P, Singh A. 2003. Rebuilding big pharma's business model. Windhover.com 21:1-10.
17. Gilson MK, Honig B. 1988. Calculation of the total electrostatic energy of a macromolecular system: solvation energies, binding energies and conformational analysis. Proteins 4:7-18.
18. Grater F, Schwarzl SM, Dejaegere A, Fischer S, Smith JC. 2005. Protein/ligand binding free energies calculated with quantum mechanics/molecular mechanics. J Phys Chem B 109:10474-10483. (Pubitemid 40786114)
19. Gronvall GK, Trent D, Borio L, Brey R, Nagao L. 2007. The FDA animal efficacy rule and Biodefense. Nat Biotechnol 25:1084-1087. (Pubitemid 47538099)
20. Guarnieri F, Mezei M. 1996. Simulated annealing of chemical potential: a general procedure for locating bound waters. Application to the study of the differential hydration propensities of the major and minor grooves of DNA. J Am Chem Soc 118:8493-8494. (Pubitemid 26305276)
21. Guarnieri F. 2004. Computational protein probing to identify binding sites. U.S. Patent 6,735,530.
22. Jencks WP. 1981. On the attribution and additivity of binding energies. Proc Natl Acad Sci USA 78:4046-4050. (Pubitemid 11010286)
23. Jorgensen WL, Ruiz-Caro J, Tirado-Rives J, Basavapathruni A, Anderson KS, Hamilton AD. 2006. Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 16:663-667. (Pubitemid 43014855)
24. Luo R, Gilson MK. 2000. Synthetic adenine receptors: direct calculation of binding affinity and entropy. J Am Chem Soc 122:2934-2937. (Pubitemid 30191053)
25. Meagher KL, Carlson HA. 2004. Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case. J Am Chem Soc 126:13276-13281. (Pubitemid 39386291)
26. Michelotti EL, Moffett KK, Nguyen D, Kelly MJ, Shetty R, Chai X, Northrop K, Namboodiri V, Campbell B, Flynn GA, Fujimoto T, Hollinger FP, Bukhtiyarova M, Springman EB, Karpusas MN. 2005. Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett 15:5274-5279. (Pubitemid 41463663)
27. Moore WR. 2005. Maximizing discovery efficiency with a computationally driven fragment approach. Curr Opin Drug Discov Dev 8:355-364. (Pubitemid 40593430)
28. Murray CW, Verdonk ML. 2002. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J Comput Aided Mol Des 16:741-753. (Pubitemid 36336183)
29. Musah RA, Jensen GM, Bunte SW, Rosenfeld RJ, Goodin DB. 2002. Artificial protein cavities as specific ligand-binding templates: characterization of an engineered heterocyclic cation-binding site that preserves the evolved specificity of the parent protein. J Mol Biol 315:845-857. (Pubitemid 34729331)
30. National Institute of Allergy and Infectious Diseases. 2003. NIAID Research Agenda for CDC Category A Agents. August. Progress Report.
31. Pitera J, Kollman P. 1998. Designing an optimum guest for a host using multimolecule free energy calculations: predicting the best ligand for Rebek's tennis ball. J Am Chem Soc 120:7557-7567. (Pubitemid 28383418)
32. Price DL, Jorgensen WL. 2001. Improved convergence of binding affinities with free energy perturbation: application to nonpeptide ligands with pp60c-src SH2 domain. J Comp Aided Mol Des 15:681-695. (Pubitemid 33014611)
33. Rizzo RC, Tirado-Rives J, Jorgensen WL. 2001. Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations. J Med Chem 44:145-154. (Pubitemid 32096659)
34. Rizzo RC, Udier-Blagovic M, Wang DP, Watkins EK, Kroger Smith MB, Smith Jr RH, Tirado-Rives J, Jorgensen WL. 2002. Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations. J Med Chem 45:2970-2987. (Pubitemid 34721519)
35. Schneider G, Fechner U. 2005. Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 4:649-663. (Pubitemid 41149759)
36. Schreiber SL. 2000. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287:1964-1969. (Pubitemid 30158663)
37. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. 2006. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534-553. (Pubitemid 43157487)
38. Simmerling C, Fox T, Kollman PA. 1998. Use of locally enhanced sampling in free energy calculations: testing and application to the anomerization of glucose. J Am Chem Soc 120:5771-5782. (Pubitemid 28305494)
39. Singh SB, Kollman PA. 1999. Calculating the absolute free energy of association of netropsin and DNA. J Am Chem Soc 121:3267-3271. (Pubitemid 29190888)
40. Singh UC, Brown FK, Bash PA, Kollman PA. 1987. An Approach to the Application of Free Energy Perturbation methods using molecular dynamics: applications to the transformations of CH3OH CH3CH3, H3O+ NH4+, glycine alanine, and alanine phenylalanine in aqueous solution and to H3O+(H2O)3-NH4+ (H2O)3 in the gas phase. J Am Chem Soc 109:1607-1614.
41. Tominaga Y, Jorgensen WL. 2004. General model for estimation of the inhibition of protein kinases using Monte Carlo simulations. J Med Chem 47:2534-2549. (Pubitemid 38580091)
42. Wang J, Morin P, Wang W, Kollman PA. 2001. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc 123:5221-5230. (Pubitemid 32910665)
43. Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, Lambert MH, Lindvall M, Nevins N, Semus SF, Senger S, Tedesco G, Wall ID, Woolven JM, Peishoff CE, Head MS. 2006. A critical assessment of docking programs and scoring functions. J Med Chem 49:5912-5931. (Pubitemid 44484938)